MJNA_Logo.png
Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Celebrates Successful Sponsorship of 2022 XII Latin American Congress of Epilepsy in Medellin, Colombia
October 20, 2022 09:00 ET | Medical Marijuana, Inc.
SAN DIEGO, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that...
NeuroSigma.png
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
October 17, 2022 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
Featured Image for Ambit Inc.
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
October 11, 2022 11:15 ET | Ambit Inc.
CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit's data-driven methodology for...
NeuroSigma.png
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
September 27, 2022 12:00 ET | NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
September 21, 2022 12:00 ET | Neurona Therapeutics
Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date in first trial participant Data Safety Monitoring Board clears advancement of...
01_PrimaryLogo_Color_BlueX-100.jpg
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
September 20, 2022 08:30 ET | Praxis Precision Medicines, Inc.
SAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs
September 07, 2022 07:30 ET | Praxis Precision Medicines, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Zeto and Next Gen Neuro Partner for Remote EEG Monitoring
August 29, 2022 09:00 ET | Zeto, Inc.
SANTA CLARA, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Zeto, Inc., a medical technology company, has announced its partnership with Next Gen Neuro, a continuous and routine EEG monitoring company,...
GMILogo_Vertical-Gradient.png
Neurostimulation Devices Market to hit USD 20.1 billion by 2030, says Global Market Insights Inc.
August 25, 2022 05:15 ET | Global Market Insights Inc.
Selbyville, Delaware, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Neurostimulation Devices Market value is set to cross USD 20.1 billion by 2030, according to a new research report by Global Market Insights...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET | Praxis Precision Medicines, Inc.
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide...